Britta Fuenfstueck appointed as new CEO of the HARTMANN GROUP
mehr
Storys zum Thema Gesundheit
- Sprache:
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
India hosts the Mahatma Gandhi International Sanitation Convention / 29th September to 2nd October 2018, New Delhi
New Delhi (ots) - Ministers and sanitation sector leaders from around the world will convene this month at the Mahatma Gandhi International Sanitation Convention (MGISC) in New Delhi. Hosted by the Government of India, this event will be an opportunity for delegates to exchange sanitation successes and best ...
mehrEuropean Society for Medical Oncology (ESMO)
ESMO emphasises importance of cancer on global health agenda at WHA
Lugano (ots) - - Indication: Picture can be downloaded free of charge under: http://www.presseportal.ch/de/nr/100006433?langid=2 - At the World Health Assembly in Geneva, ESMO delivered two statements positioning cancer as a priority on the WHO global agenda. ESMO advocated the strengthening of health systems to achieve Universal Health Coverage and to provide ...
mehrHitachi Medical Systems Europe Holding AG
Hitachi Medical Systems Europe announces "ScanSync" - a new function for diagnostic ultrasound that reduces the burden on operators - which is to be supported by the "ARIETTA Prologue"
Vienna (ots) - - Indication: Picture can be downloaded free of charge under: http://www.presseportal.ch/de/nr/100012989?langid=2 - This function enables the operation of the diagnostic ultrasound system via auto detection of transducer movement. Hitachi Medical Systems Europe, a wholly owned subsidiary of Hitachi, ...
mehrPersonnel Change in Executive Board of L&R
Vienna/Rengsdorf (ots) - In January 2018, a change in the Executive Board of manufacturer and supplier of medical devices, Lohmann & Rauscher (L&R), took place after the former Chief Commercial Officer, Markus Sebastian, had resigned. The Advisory Board and the CCO mutually agreed that Markus Sebastian is going to leave the Lohmann & Rauscher Corporate Group by the end of January 2018 to pursue new tasks and face new ...
mehrFresenius Medical Care AG & Co. KGaA
Fresenius Medical Care to acquire NxStage Medical, Inc. to strengthen its vertically integrated dialysis business
Bad Homburg (ots) - Acquisition of NxStage Medical, Inc. would: - position Fresenius Medical Care as a global leader in home dialysis - establish U.S. presence in the critical care space - further enhance clinical outcomes and patient empowerment - support strategic initiative of vertical integration and Care ...
mehr
Hitachi Medical Systems Europe Holding AG
Hitachi Aloka will present the ARIETTA V70*1 with enhanced Elastography functions
Tokyo, Japan (ots) - At this year's ECR (European Congress of Radiology), March 2-6 in Vienna, Hitachi Aloka will present ARIETTA V70*1 with enhanced Elastography functions. As the pioneer of Elastography, Hitachi Aloka Medical, Ltd. maintains its leadership in this field, providing solutions that can drive Elastography examinations to a new stage by equipping their ...
mehrHitachi Medical Systems Europe Holding AG
Hitachi Aloka launches two new, highly flexible Diagnostic Ultrasound Systems, ARIETTA Precision and ARIETTA Prologue
Tokyo, Japan (ots) - At this year's ECR (European Congress of Radiology), March 2-6 in Vienna, Hitachi Aloka Medical launches two new Diagnostic Ultrasound Systems, the ARIETTA Precision and the ARIETTA Prologue. The demand for diagnostic ultrasound examinations in healthcare areas such as advanced acute treatment, ...
mehrEuropean Society for Medical Oncology (ESMO)
ESMO announces annual medical oncology congress platform in Europe from 2016
Lugano, Switzerland (ots) - The European Society for Medical Oncology, the pan-European association representing medical oncologists in Europe and beyond, has announced that it will be organising an annual Congress in Europe from 2016. A record 19,809 participants from 134 countries gathered at ESMO 2014 in Madrid to hear the results of trials which included ...
mehrBoehringer Ingelheim's afatinib Achieves Primary Endpoint in Global Phase III Study in Recurrent/Metastatic Head and Neck Squamous Cell Cancer
Ingelheim, Germany (ots/PRNewswire) - - Results from the LUX-Head & Neck 1 study show afatinib* significantly delayed tumour growth versus chemotherapy in patients following failure of their previous treatment, reducing the risk for disease progression by 20% - Head and neck cancer has a very poor prognosis with no ...
mehrDeutsche Gesetzliche Unfallversicherung (DGUV)
Publication of the programme for the World Congress on Safety and Health at Work 2014
Berlin (ots) - Top-level guests at the world's biggest safety & health convention - Day passes now bookable - Information for journalists A world without serious accidents at work - this is the vision that will be discussed by politicians, scientists and experts from all over the world at the XX World Congress on Safety and Health at Work, which is taking place in ...
mehrOne Million DocCheckers / Europe's largest healthcare community reaches seven figures
Cologne (ots) - The DocCheck Community reached the magic number of one million users in April, putting it in a clear pole position among European healthcare communities. DocCheck has been providing GPs, consultants, students, pharmacists, nurses, pharmacy technicians and paramedics with healthcare-related news and services for more than 15 years. Launched in 1996 with ...
mehr
CGC Cramer-Gesundheits-Consulting GmbH
CYTONET SUBMITS EUROPEAN APPROVAL APPLICATION FOR LIVER CELL THERAPY TO TREAT UREA CYCLE DISORDERS IN CHILDREN
Weinheim/Germany (ots) - International biotechnology firm Cytonet announced today that the European Medicines Agency (EMA) has validated its Marketing Authorization Application (MAA) seeking approval for its liver cell therapy for the treatment of Urea Cycle Disorders (UCD) in children. UCD is a life-threatening ...
mehrDeutsche Gesetzliche Unfallversicherung (DGUV)
Last chance to submit contributions to the XX World Congress on Safety and Health at Work 2014
Berlin (ots) - The registration period for contributions to the XX World Congress on Safety and Health at Work 2014 ends on the 30th of November 2013. Participants who wish to make a contribution to a symposium are invited to submit an English-language summary thereof online at www.safety2014germany.com/papers. ...
mehrBG ETEM - Berufsgenossenschaft Energie Textil Elektro Medienerzeugnisse
International Media Festival for Prevention: The best films for occupational safety and health will be awarded
Frankfurt (ots) - Films and multimedia applications are vital instruments of safety and health at work. Whether for the purpose of increasing risk awareness on the part of employees or providing information on comprehensive safety topics: moving images support the transfer of knowledge. Media makers have to keep ...
mehrDocCheck goes India / DocCheck announces cooperation with India-based healthcare service
Cologne (ots) - Well-spread throughout Europe, DocCheck continues to expand into new markets. In order to provide healthcare professionals around the globe with its unique services, DocCheck has now settled an exclusive cooperation with Indian experts D2L Pharma Research Solutions. The cooperation encompasses the fast-growing healthcare market of India, thus granting ...
mehrWorld Malaria Day: when a simple initiative conveys great results
Limburgerhof, Germany (ots) - - Interceptor® bed nets key factor for decrease in malaria infection in Jabote community (Brazil) - Positive spiral effect: less malaria, more kids in school - Cross reference: Pictures are available via epa european pressphoto agency and can be downloaded free of charge at: http://www.presseportal.de/pm/16344/basf_se/?keygroup=bild - April 25th marks the fourth annual celebration of World ...
mehrBoehringer Ingelheim Initiates First Phase III Clinical Trial in Ovarian Cancer
Ingelheim, Germany (ots/PRNewswire) - Boehringer Ingelheim announced today the initiation of a new phase III clinical trial to evaluate one of its two late-stage oncology pipeline compounds for the treatment of patients with advanced ovarian cancer. The clinical study, called LUME-Ovar-1 trial, investigates the compound BIBF 1120, a novel oral anti-angiogenic agent[1], ...
mehr
Flibanserin Demonstrates Efficacy and Tolerability in Pivotal Phase III Trials in Pre-Menopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Ingelheim, Germany, November 16 (ots/PRNewswire) - - Results Support Flibanserin as a Potential Treatment for HSDD, an Under-Recognised Women's Sexual Health Condition - For Medical Media, Outside the US Only Data from pooled, pivotal Phase III clinical trials demonstrate that flibanserin 100mg taken once daily at ...
mehrBoehringer Ingelheim Receives Approval From the European Commission for Mirapexin(R)/Sifrol(R) Prolonged-Release, Once Daily Tablet for the Treatment of Parkinson's Disease
Ingelheim, Germany (ots/PRNewswire) - - New Formulation Brings the Established Efficacy of Mirapexin(R)/Sifrol(R) to Patients With Parkinson's Disease in the Convenience of a Once Daily Dose Boehringer Ingelheim today announced that the Mirapexin(R)/Sifrol(R) (pramipexole) new prolonged-release , once daily tablet ...
mehrBoehringer Ingelheim's Diabetes Pipeline Continues to Advance as the Company Announces Conclusion of Robust Phase III Pivotal Trials Programme for linagliptin
Ingelheim, Germany (ots/PRNewswire) - - For Non-US Healthcare Media Following the release of linagliptin Phase II data earlier this year, Boehringer Ingelheim has now announced the conclusion of the linagliptin pivotal Phase III clinical trials. The company confirmed that first results from the Phase III clinical ...
mehrBoehringer Ingelheim to Commence Phase III Study Investigating the Role of BIBW 2992 (Tovok(TM)) as First-Line Treatment for Non-Small Cell Lung Cancer (NSCLC) Patients With EGFR Mutations
Ingelheim, Germany (ots/PRNewswire) - - Data From Phase II Studies Investigating BIBW 2992 (Tovok(TM)) and BIBF 1120 (Vargatef(TM)) in NSCLC Patients Presented at 13th World Conference on Lung Cancer (WCLC) INGELHEIM, Germany, August 3 /PRNewswire/ -- Boehringer Ingelheim announced today at the International ...
mehrHead-to-Head Trial Demonstrates Viramune(R)'s Similar Efficacy and Superior Effect on Lipid Profile Compared to atazanavir/ritonavir
Cape Town, South Africa (ots/PRNewswire) - - For Medical Media Outside the US Only Results from the ARTEN* trial presented at the 5th International AIDS Society (IAS) conference in Cape Town, South Africa demonstrated non-inferiority regarding efficacy between Viramune(R) (nevirapine) and ritonavir boosted ...
mehrEuropean Commission Approves Statement on Lipid Improvement for VIRAMUNE(R) Label
Ingelheim, Germany (ots/PRNewswire) - - For Medical Media Outside the US only Boehringer Ingelheim announced today that the European Commission has approved an update of the Summary of Product Characteristics (SmPC) for VIRAMUNE(R) (nevirapine) in the treatment of patients with HIV. The decision followed a positive recommendation by the Committee for Medical Products ...
mehr
Boehringer Ingelheim Receives Positive Recommendation From European Scientific Committee for a New Once Daily Mirapexin(R) (Pramipexole) Formulation for the Treatment Of Parkinson's Disease
Ingelheim, Germany (ots/PRNewswire) - - For non-U.S. Healthcare Media Boehringer Ingelheim announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion recommending the approval of a once daily formulation for Mirapexin(R) / ...
mehrNew Data From Boehringer Ingelheim's Ongoing Linagliptin Trial Programme Show Promising Safety and Efficacy Results
Ingelheim, Germany (ots/PRNewswire) - - Results From Linagliptin Study in Type 2 Diabetes Patients Who Were Inadequately Controlled on Metformin Therapy Alone, Presented at Major Diabetes Meeting Study results presented for the first time in the scientific sessions of this year's American Diabetes Association Annual ...
mehrBoehringer Ingelheim and the World Stroke Organization Announce Partnership in the World Stroke Academy
Ingelheim, Germany (ots/PRNewswire) - - For Healthcare Media Outside the U.S.A., Canada, and Japan Boehringer Ingelheim announced today that it will become the founding sponsor of the World Stroke Academy, a novel training initiative for stroke professionals being developed by the World Stroke Organization (WSO). ...
mehrOutcome of New Mirapexin(R)/Sifrol(R) (Pramipexole) Study set to Change Treatment of Depressive Symptoms in Parkinson's Disease
Ingelheim, Germany (ots/PRNewswire) - - New Study Shows That Mirapexin(R)/Sifrol(R) (Pramipexole) Relieves Depressive Symptoms of Parkinson's Disease (PD), a Common Non-Motor Symptom Affecting PD Patients' Quality of Life - For Non-US Healthcare Media To view the Multimedia News Release, go to: ...
mehrNew Study Results Support Once Daily, Prolonged Release Formulation of Mirapexin(R)/Sifrol(R) (Pramipexole) for the Treatment of Parkinson's Disease
Ingelheim, Germany (ots/PRNewswire) - - Data for the Once Daily Mirapexin(R)/Sifrol(R) (Pramipexole) Formulation Under Development Show Efficacy, Safety and Tolerability Outcomes Comparable to the Current Immediate Release Formulation for the Treatment of Parkinson's Disease For non-US Healthcare Media First data ...
mehrNo Increased Risk of Treatment-Induced Augmentation in Restless Legs Syndrome (RLS) Demonstrated in Long-Term Placebo-Controlled Study With Mirapexin(R) / Sifrol(R) (Pramipexole)
Ingelheim, Germany (ots/PRNewswire) - - For Healthcare Media outside the U.S.A. New data presented today at the 61st Annual Meeting of the American Academy of Neurology (AAN), in Seattle, U.S.A. show that augmentation did not significantly differ in RLS patients treated with Mirapexin(R) /Sifrol(R) (pramipexole*) ...
mehr
Vorherige12345678Nächste